Odyssey Thera
will analyze drug candidates from a number of preclinical programs for
Mitsubishi Tanabe Pharma. Odyssey Thera will apply its patented protein-fragment complementation assay, high-context screening infrastructure, institutional knowledge, and data analysis strategies in the collaboration to yield insights related to drug selectivity, safety, and mechanisms of action.
Odyssey also reports the issuance of a Japanese patent entitled, “Protein fragment complementation assays for the detection of biological or drug interactions.”